Incyte

Incyte Corporation
Public
Traded as NASDAQ: INCY
NASDAQ-100 Component
S&P 500 Component
Industry pharmaceutical company
Founded 1991 (1991)
Headquarters Wilmington, Delaware, United States
Key people
 Hervé Hoppenot (President and CEO, 2014)
Revenue Increase $US 1.5 billion (2017)
Increase $US $300 million(2017)
Total assets Increase $US 1.504 billion(2017)
Total equity Increase $US 1.632 billion(2017)
Number of employees
 ~700[1]
Website www.incyte.com
Footnotes / references
[2]

Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware.[3] The company was founded in Palo Alto, California in 1991 and went public in 1993.[1]

Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States.[3]

As of 2014 the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[4][5] It gained EU approval in February 2017.[6] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[7][8]

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[9][10]

Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma.[11]

History

In 2014, Incyte named Hervé Hoppenot president and CEO.[12] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[12]

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[13]

References

  1. 1 2 Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
  2. ↑ Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, retrieved May 6, 2012
  3. 1 2 Natoli, Cori Anne (May 5, 2012), "Incyte looks to ride on drug's success", The News Journal, retrieved May 6, 2012
  4. ↑ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Retrieved 2 Mar 2015.
  5. ↑ "Baricitinib" (pdf). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
  6. ↑ "Olumiant: Authorisation details". European Medicines Agency. 16 March 2017.
  7. ↑ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
  8. ↑ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
  9. ↑ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European journal of cancer (Oxford, England : 1990). 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
  10. ↑ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
  11. ↑ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. Retrieved 2015-12-29.
  12. 1 2 "People". Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 41.
  13. ↑ "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.